Trial reportNaunyn-Schmiedeberg's archives of pharmacology2026
Efficacy and safety of vunakizumab between super responders and non-super responders of patients with moderate-to-severe plaque psoriasis: a post-hoc exploratory analysis of a phase III trial.
Trial report in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04839016 (A Randomized, Double-blind, Multicenter, Placebo-controlled, Phase III Adaptive Study of SHR-1314 to Assess Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Multicenter, Placebo-controlled, Phase III Adaptive Study of SHR-1314 to Assess Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Super responders refer to a subset of patients with psoriasis who achieve a rapid and good treatment response to biologics. This post-hoc exploratory analysis aimed to compare the efficacy and safety of vunakizumab between super responders and non-super responders of patients with moderate-to-severe plaque psoriasis. This was a post-hoc exploratory analysis of a phase III trial (NCT04839016). Patients with moderate-to-severe plaque psoriasis receiving vunakizumab who achieved and maintained 100% improvement in the psoriasis area severity index (PASI 100) score at week W12/W16 were defined as W12/W16 super responders; those at W24 and W28 were defined as W24/W28 super responders. A total of 461 patients were enrolled; 154 (33.4%) and 224 (48.6%) patients were W12/W16 and W24/W28 super responders. PASI 75/90/100 and static physician's global assessment 0/1 response rates at most time points were higher in W12/W16 and W24/W28 super responders than corresponding non-super responders (all P < 0.05). Improvement in patient-reported outcomes (PROs) at most time points was better in W12/W16 and W24/W28 super responders than corresponding non-super responders (all P < 0.05). The incidence of any adverse events was not different between super responders and non-super responders (all P > 0.05). After vunakizumab treatment, super responder status is associated with better treatment response and PROs in patients with moderate-to-severe plaque psoriasis, while the safety is not affected by this status.
Indexed as
Identifiers
41483190What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.